research on glp 1 drugs GLP-1 Receptor Agonist Market Size & Analysis, 2026-2033 GLP-1 Receptor Agonists Obesity Drugs
Description
Partner with GenScript today to advance your GLP-1 based therapeutics.
Tirzepatide 15 mg led to higher discontinuation rate of study medication due to adverse events regardless of comparator, while all tirzepatide doses were safe in terms of serious adverse events and mortality
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
HIGHLIGHTS: Grab-and-go stick packs
Explore the implications of proposed changes to GLP-1 medication coverage and their impact on Medicare and Medicaid health plans
